Lupus & antiphospholipid syndrome
Anti-thrombotics and major adverse cardiovascular events in anti-phospholipid syndrome: a cross-sectional study using the 2016–2018 National Inpatient Sample database
Authors' conclusion
Patients with APS are most likely to benefit from anti-coagulant therapy in reducing MACE.
Study context
- Population
- Patients with anti-phospholipid syndrome (APS) in the NIS database, 2016–2018
- Participants
- 13,947 patients
- Exposure
- Anti-thrombotic regimens and major adverse cardiovascular events (MACE)/death in APS
- Outcome
- Two primary outcomes: MACE and death
Methodological detailsNational Inpatient Sample 2016-2018, multivariate logistic regression
- National Inpatient Sample 2016-2018
- Multivariate logistic regression
Main finding
As reported in the abstract
MACE
Odds ratio (95% CI)P value
Anti-coagulantsalso reduced odds of each MACE subcomponent
0.68(0.62–0.76)
P < 0.001No anti-coagulants
1.47(1.24–1.72)
P < 0.001Each MACE subcomponent, as printed
Observational data: associations, not effects.
Further findings
Co-primary: death
| OR (95% CI) | P value | ||
|---|---|---|---|
| Anti-coagulantsOnly class with apparent mortality benefit | 0.64 (0.49–0.84) | P = 0.001 | |
| 0.512Odds ratio (log scale) |
MACE and death in higher-risk subgroups (AF and thrombocytopenia)
- Full anti-coagulation the only anti-thrombotic class significantly affecting MACE odds, protective, but no mortality benefit
Original publication
Anti-thrombotics and major adverse cardiovascular events in anti-phospholipid syndrome: a cross-sectional study using the 2016–2018 National Inpatient Sample database. Scand J Rheumatol. Published 16 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →